SF3B1 and myelodysplastic syndrome: We then tested the combination of XPO1i (eltanexor) with venetoclax, A1331852, and navitoclax using increasing concentrations of each drug in SF3B1 wildtype, SF3B1 mutant, and various AML/MDS cell lines (Fig. 5C).